These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 27233495)

  • 1. Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
    Wen WX; Soo JS; Kwan PY; Hong E; Khang TF; Mariapun S; Lee CS; Hasan SN; Rajadurai P; Yip CH; Mohd Taib NA; Teo SH
    Breast Cancer Res; 2016 May; 18(1):56. PubMed ID: 27233495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.
    Liu J; Sieuwerts AM; Look MP; van der Vlugt-Daane M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
    PLoS One; 2016; 11(8):e0161731. PubMed ID: 27552096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.
    Kim SH; Ahn S; Suh KJ; Kim YJ; Park SY; Kang E; Kim EK; Kim IA; Chae S; Choi M; Kim JH
    Breast Cancer Res Treat; 2020 Oct; 183(3):697-704. PubMed ID: 32715441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of APOBEC3A/3B germline deletion polymorphism in breast, cervical and oral cancers from South India and its impact on miRNA regulation.
    Revathidevi S; Manikandan M; Rao AK; Vinothkumar V; Arunkumar G; Rajkumar KS; Ramani R; Rajaraman R; Ajay C; Munirajan AK
    Tumour Biol; 2016 Sep; 37(9):11983-11990. PubMed ID: 27155849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of functional germline variants and a deletion polymorphism in APOBEC3A and APOBEC3B on breast cancer risk and survival in a Swedish study population.
    Göhler S; Da Silva Filho MI; Johansson R; Enquist-Olsson K; Henriksson R; Hemminki K; Lenner P; Försti A
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):273-6. PubMed ID: 26320772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer.
    Nik-Zainal S; Wedge DC; Alexandrov LB; Petljak M; Butler AP; Bolli N; Davies HR; Knappskog S; Martin S; Papaemmanuil E; Ramakrishna M; Shlien A; Simonic I; Xue Y; Tyler-Smith C; Campbell PJ; Stratton MR
    Nat Genet; 2014 May; 46(5):487-91. PubMed ID: 24728294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation.
    Cescon DW; Haibe-Kains B; Mak TW
    Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2841-6. PubMed ID: 25730878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types.
    Chen Z; Wen W; Bao J; Kuhs KL; Cai Q; Long J; Shu XO; Zheng W; Guo X
    BMC Med Genomics; 2019 Sep; 12(1):131. PubMed ID: 31533728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune gene expression profiling reveals heterogeneity in luminal breast tumors.
    Zhu B; Tse LA; Wang D; Koka H; Zhang T; Abubakar M; Lee P; Wang F; Wu C; Tsang KH; Chan WC; Law SH; Li M; Li W; Wu S; Liu Z; Huang B; Zhang H; Tang E; Kan Z; Lee S; Park YH; Nam SJ; Wang M; Sun X; Jones K; Zhu B; Hutchinson A; Hicks B; Prokunina-Olsson L; Shi J; Garcia-Closas M; Chanock S; Yang XR
    Breast Cancer Res; 2019 Dec; 21(1):147. PubMed ID: 31856876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline APOBEC3B deletion influences clinicopathological parameters in luminal-A breast cancer: evidences from a southern Brazilian cohort.
    Vitiello GAF; de Sousa Pereira N; Amarante MK; Banin-Hirata BK; Campos CZ; de Oliveira KB; Losi-Guembarovski R; Watanabe MAE
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1523-1532. PubMed ID: 32285256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer.
    Radmanesh H; Spethmann T; Enßen J; Schürmann P; Bhuju S; Geffers R; Antonenkova N; Khusnutdinova E; Sadr-Nabavi A; Shandiz FH; Park-Simon TW; Hillemanns P; Christiansen H; Bogdanova N; Dörk T
    Breast Cancer Res Treat; 2017 Feb; 162(1):31-37. PubMed ID: 28062980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population.
    Marouf C; Göhler S; Filho MI; Hajji O; Hemminki K; Nadifi S; Försti A
    BMC Cancer; 2016 Feb; 16():165. PubMed ID: 26920143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.
    Middlebrooks CD; Banday AR; Matsuda K; Udquim KI; Onabajo OO; Paquin A; Figueroa JD; Zhu B; Koutros S; Kubo M; Shuin T; Freedman ND; Kogevinas M; Malats N; Chanock SJ; Garcia-Closas M; Silverman DT; Rothman N; Prokunina-Olsson L
    Nat Genet; 2016 Nov; 48(11):1330-1338. PubMed ID: 27643540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative genomic analysis reveals functional diversification of APOBEC gene family in breast cancer.
    Zhang Y; Delahanty R; Guo X; Zheng W; Long J
    Hum Genomics; 2015 Dec; 9():34. PubMed ID: 26682542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers.
    Tsuboi M; Yamane A; Horiguchi J; Yokobori T; Kawabata-Iwakawa R; Yoshiyama S; Rokudai S; Odawara H; Tokiniwa H; Oyama T; Takeyoshi I; Nishiyama M
    Breast Cancer; 2016 Sep; 23(5):780-8. PubMed ID: 26476745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline APOBEC3B deletion increases somatic hypermutation in Asian breast cancer that is associated with Her2 subtype, PIK3CA mutations and immune activation.
    Pan JW; Zabidi MMA; Chong BK; Meng MY; Ng PS; Hasan SN; Sandey B; Bahnu S; Rajadurai P; Yip CH; Rueda OM; Caldas C; Chin SF; Teo SH
    Int J Cancer; 2021 May; 148(10):2489-2501. PubMed ID: 33423300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers.
    Sieuwerts AM; Willis S; Burns MB; Look MP; Meijer-Van Gelder ME; Schlicker A; Heideman MR; Jacobs H; Wessels L; Leyland-Jones B; Gray KP; Foekens JA; Harris RS; Martens JW
    Horm Cancer; 2014 Dec; 5(6):405-13. PubMed ID: 25123150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.
    Law EK; Sieuwerts AM; LaPara K; Leonard B; Starrett GJ; Molan AM; Temiz NA; Vogel RI; Meijer-van Gelder ME; Sweep FC; Span PN; Foekens JA; Martens JW; Yee D; Harris RS
    Sci Adv; 2016 Oct; 2(10):e1601737. PubMed ID: 27730215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer.
    Gansmo LB; Sofiyeva N; Bjørnslett M; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
    Sci Rep; 2021 Dec; 11(1):23463. PubMed ID: 34873230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APOBEC3B deletion impacts on susceptibility to acquire HIV-1 and its advancement among individuals in western India.
    Singh H; Marathe SD; Nain S; Nema V; Ghate MV; Gangakhedkar RR
    APMIS; 2016 Oct; 124(10):881-7. PubMed ID: 27522954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.